PSTX: Poseida Net earnings per share (EPS TTM)

Public company logo of Poseida Therapeutics Inc (PSTX)

Poseida Therapeutics (PSTX) generates revenue by licensing its piggyBac platform to develop oncology drugs in collaboration with global partners. This 12-month net income per share chart shows that the metric has settled at -0.63. High R&D risks are mitigated by strategic alliances with pharma behemoths. Its status as a scientific elite in genetic engineering provides the company with an impeccable level of investor confidence.

PSTX (Poseida Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 01/18/2025

Poseida Therapeutics - analytical breakdowns and key metrics (PSTX)

- share price and expert price forecast:
Stock Quotes Poseida Therapeutics, Inc.|PSTX - Fair Value Consensus
- market capitalization information:
Market Capitalization Poseida Corp|PSTX - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share Poseida Therapeutics|PSTX - Total Stockholders' Equity|Market Value to Book Value Ratio poseida.com|PSTX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Poseida Therapeutics|PSTX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Poseida Therapeutics|PSTX - Aggregate Debt Obligations|Debts to Book Capitalization Poseida|PSTX - Long-Term Indebtedness|Company Short-Term Debts Poseida Therapeutics|Quick Liquidity poseida.com
- net income and valuation multiples indicators:
PSTX - Company Profit|Projected Future Earnings Poseida Therapeutics|PSTX - Market Cap to Earnings|Projected Price to Earnings Poseida|PSTX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Poseida Therapeutics, Inc.|PSTX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Poseida Therapeutics|PSTX - Earnings per share for the trailing year|Quarterly EPS earnings growth poseida.com|PSTX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Poseida Therapeutics
- revenue and sales proceeds data:
PSTX - Company Sales Revenue|Projected Sales Volume poseida.com|PSTX - P/S Multiple|Price-to-Projected Revenue Ratio Poseida Therapeutics Inc
General company analysis:poseida.com (PSTX)
Mass-produced product of Poseida Corp

Poseida Therapeutics (PSTX) is developing innovative gene therapy methods in partnership with Roche. By analyzing the company's net income per share TTM, an investor can observe profitability trends over the year. This metric is calculated as the ratio of total net income to the number of common shares, excluding reporting time lags. The current value of -0.63 reflects the real-time efficiency of the capitalization of its developments. This indicator allows for an objective assessment of the business's financial stability.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (Sana Biotechnology, Inc.)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics Inc|RNAC (Selecta Biosciences) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cellectis.com CLLS|Earnings per share for the last twelve months Caribou Biosciences, Inc. (CRBU)|Earnings per share for the last twelve months TIL (Instil Bio, Inc)|Earnings per share for the last twelve months Genenta GNTA|centurytx.com - Earnings per share for the last twelve months|JSPR: Net earnings per share for the last 12 months|Earnings per share for the trailing year SNTI (sentibio.com)|ADAP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year CERo Therapeutics Holdings, Inc. CERO|TCRT (Alaunos Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months achillestx.com ACHL|Earnings per share for the last twelve months CARGO Therapeutics, Inc. (CRGX)|2seventy bio, Inc. - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell)